Metabolic & Cardiometabolic
arabinoxylan dietary fiber decreases LDL cholesterol
In plain terms: Does the wheat fiber arabinoxylan actually lower LDL cholesterol?
Arabinoxylan does modestly lower LDL in small trials via bile-acid loss, but calling it the single "most effective" fiber overstates the evidence versus beta-glucan and psyllium.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
<!-- vault-context --> Norwitz affirms this claim. Consensus below reflects independent literature only.
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ho, Sievenpiper, Zurbau, Blanco Mejia, Jovanovski, Au-Yeung, Jenkins, Vuksan 2016 · Br J Nutr | meta-analysis | supports | high | OFF-SCOPE for an arabinoxylan claim: the pooled exposure is oat beta-glucan alone — 'only RCT that investigated the effects of supplementing β-glucan from oat products on LDL-cholesterol, non-HDL-cholesterol and/or apoB were included in the analysis' — and the word 'arabinoxylan' does not occur anywhere in the article. The prior extract's 'arabinoxylan-class' label was an interpolation, not the paper's: beta-glucan is a mixed-linkage (1->3)(1->4)-beta-D-glucan, chemically distinct from arabinoxylan's arabinose-substituted xylan backbone, and where wheat/rye material appears in this literature it sits on the CONTROL side of the included trials. What the paper does show, for the beta-glucan claim rather than this one: 'In total, fifty-eight trials (n 3974) were included' and 'A median dose of 3·5 g/d of oat β-glucan significantly lowered LDL-cholesterol (−0·19; 95 % CI −0·23, −0·14 mmol/l, P<0·00001), non-HDL-cholesterol (−0·20; 95 % CI −0·26, −0·15 mmol/l, P<0·00001) and apoB (−0·03; 95 % CI −0·05, −0·02 g/l, P<0·0001) compared with control interventions.' |
| Lu 2000 · Am J Clin Nutr | RCT | mixed | moderate | Wheat arabinoxylan reduced postprandial glucose in normoglycemic subjects; lipid/LDL effects not established in this acute study. |
| Hartvigsen 2014 · Eur J Clin Nutr | RCT | tested-null | moderate | Concentrated arabinoxylan improved postprandial glucose/appetite in metabolic syndrome but did not demonstrate meaningful LDL lowering. |
| Garcia 2006 · Br J Nutr | RCT | mixed | moderate | 15g/day arabinoxylan lowered fasting glucose, triglycerides and apoA-1 but showed no significant effect on apoB or LDL-related fractions. |
| Lancaster 2022 · Cell Host Microbe | RCT | supports | moderate | n=18 crossover purified-fiber feeding: arabinoxylan significantly cut LDL & raised bile acids; the exact paper Norwitz cites, small n. |
| Whitehead A, Beck EJ, Tosh S, Wolever TMS 2014 · Am J Clin Nutr | meta-analysis | tested-null | high | OFF-SCOPE for an arabinoxylan claim. The measured exposure is 'Oat β-glucan (OBG)' and nothing else: 'A meta-analysis was performed on 28 RCTs comparing ≥3 g OBG/d with an appropriate control.' The string 'arabinoxylan' occurs zero times in the full text, Table 1, or Supplemental Tables 1-4. Worse for the inference, wheat bran and wheat fibre - arabinoxylan's food matrix - are on the CONTROL side of ten of the 28 included trials, thirteen comparison rows (Anderson, Donazzolo, Uusitupa, Wolever 4L/3M/4M/3H, Abrahamsson, Kestin vs wheat bran; Kabir, Kerckhoffs, Theuwissen, Whyte vs wheat fibre), chosen precisely as low-viscous-fibre comparators. The prior extracted was an explicit mechanistic-class extrapolation - 'the mechanistic class to which wheat arabinoxylan belongs' - not a measurement, and it asserted a lowering effect while the note recorded stance tested-null, so it was internally inconsistent as well as off-scope. What the paper does establish for the beta-glucan arm: 'of −0.25 mmol/L (95% CI: −0.30, −0.20' on LDL. Nothing here weighs on arabinoxylan in either direction. |
| Schioldan 2018 · Eur J Nutr | RCT | mixed | moderate | 4-wk arabinoxylan+resistant-starch diet in metabolic syndrome improved postprandial metabolism but did not significantly lower fasting LDL vs refined-carb. |
| Lu 2004 · Diabetologia/Eur J Clin Nutr | RCT | mixed | low | Arabinoxylan-rich wheat fiber improved glycaemic control in T2D; lipid/LDL benefit not the primary or robust finding. |
| Hall 2019 · Cell Metab | RCT | tested-null | moderate | Context disconfirmer: fiber alone is one lever; whole-diet trials show LDL driven by many factors, AX not uniquely dominant. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.